Post-earnings recap
Reported
Thu, Oct 30, 2025
EPS actual
$2.90
EPS est.
$0.46
EPS surprise
+526.35%
1-day move
-6.65%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Alnylam Pharmaceuticals reported a significant EPS beat, which indicates strong profitability relative to expectations. However, the stock dropped 6.65% in reaction, likely due to the lack of revenue details and future guidance, leaving investors uncertain about the company's growth trajectory. The defensive tone from management may have contributed to the negative stock reaction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.90 | N/A | +526.35% |
| Revenue | N/A | N/A | N/A |
Management acknowledged the strong EPS result but expressed concerns about market conditions. They did not provide a detailed outlook for future performance.
Management highlighted the unexpected EPS performance but did not provide further details on revenue.
They emphasized ongoing challenges in the market without offering specific guidance.